MGTA

Magenta Therapeutics, Inc. (MGTA) | Rumor.io

Magenta Therapeutics

MGTA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MGTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 4

Magenta Therapeutics, Inc. ($MGTA) terminated a $26M lease liability, saving ~$15M, amid market volatility.
The company's reverse merger is expected to impact its financials, with some investors expressing concerns about executive compensation and the company's lifeblood being drained.
Technical indicators suggest $MGTA's price may increase, with a recent MACD Histogram turn negative and a break below the lower Bollinger Band.

Generated by AI

Sentiment

Of the messages about MGTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Dec 12

$MGTA's positive results and conference call tomorrow are generating excitement among investors, with the stock experiencing a major after-hours bounce and a 52% increase in price.
Magenta Therapeutics' strong cash position, with $125m in the bank, is providing a solid foundation for the company's future, particularly if the FDA grants approval to transition to transplant-eligible AML/MDS in 1H23.
The stock's price action is being driven by a combination of positive data and a strong biotech/bio pharma theme, with investors anticipating good data from the company's oral presentation at ASH and a potential breakout above $2.

Generated by AI

Topics

Of the messages about MGTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

May 3

Magenta Therapeutics, Inc. ($MGTA) has entered into a merger agreement with Dianthus Therapeutics, a privately held, clinical-stage biotechnology company.
The combined company will focus on next-generation complement inhibitors, including the Phase 1 DNTH103 trial for autoimmune diseases.
The merger is an all-stock transaction, with Magenta shares halted in premarket trading and trading to resume after the announcement.

Generated by AI

Community

Of the messages about MGTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Also Discussed

Investors talking about MGTA also mention

#	Name	Attention
1	Sera Prognostics, Inc. Class A Common StockSERA	0%0
2	CNTA - Centessa Pharmaceuticals plc	——
3	HARP - Harpoon Therapeutics, Inc.	——
4	TERN - Terns Pharmaceuticals, Inc.	——
5	ImageneBio, Inc.IKNA	0%0
6	ACHL - Achilles Therapeutics plc	——
7	NLTX - Neoleukin Therapeutics, Inc.	——
8	GRPH - Graphite Bio, Inc.	——
9	CYT - Cyteir Therapeutics, Inc.	——
10	Cryo-Cell International, Inc.CCEL	0%0